We are live on ! Find out more

216 hedge funds and large institutions have $1.62B invested in Genmab in 2023 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 75 increasing their positions, 94 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more call options, than puts

Call options by funds: $6.37M | Put options by funds: $4.18M

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

3.38% less ownership

Funds ownership: 69.42%66.04% (-3.4%)

9% less funds holding

Funds holding: 237216 (-21)

16% less capital invested

Capital invested by funds: $1.94B → $1.62B (-$318M)

20% less repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 94

40% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 42

Holders
216
Holders Change
-21
Holders Change %
-8.86%
% of All Funds
3.44%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
25
Increased
75
Reduced
94
Closed
42
Calls
$6.37M
Puts
$4.18M
Net Calls
+$2.19M
Net Calls Change
+$2.55M
Name Holding Trade Value Shares
Change
Change in
Stake
PWS
251
Paragon Wealth Strategies
Florida
-$27.1K -640 Closed
First Manhattan
252
First Manhattan
New York
-$25.6K -604 Closed
HCM
253
Hollencrest Capital Management
California
-$23.7K -560 Closed
AWM
254
Accurate Wealth Management
Florida
-$21.6K -500 Closed
IA
255
IFP Advisors
Florida
-$26K -499 Closed
JWM
256
Janiczek Wealth Management
Colorado
-$3.6K -90 Closed
CCA
257
Column Capital Advisors
Indiana
-$2.16K -51 Closed

GMAB Hedge Fund Activity: Q1 2023 in Review

216 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q1 2023, worth a combined $1.62B — down 16% from $1.94B a quarter earlier.

Sellers outnumbered buyers: 42 funds closed out of GMAB and 25 opened new positions — a net loss of 17 holders — while 94 trimmed existing stakes and 75 added.

The largest buyer was Envestnet Asset Management, adding an estimated $22.5M. The largest seller was Arrowstreet Capital, cutting an estimated $28.5M.

  • 216 institutional investors held Genmab (GMAB) as of Q1 2023, down from 237 in Q4 2022.
  • Funds reported $1.62B of Genmab stock for Q1 2023, down 16% quarter-over-quarter.
  • 25 funds opened new Genmab positions in Q1 2023 and 42 closed out, a net change of -17 holders.
  • The largest Genmab buyer in Q1 2023 was Envestnet Asset Management, an estimated $22.5M added.
  • The largest Genmab seller in Q1 2023 was Arrowstreet Capital, an estimated $28.5M sold.

Based on aggregated 13F filings for Q1 2023.